Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02009761 · ClinicalTrials.gov registry record · Phase 1
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02009761 is a Phase 1 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 6 participants.
The verdict
NCT02009761, a Phase 1 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.
Interventions
- DRUG BI 655064
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-12-18 |
| Est. Completion | 2016-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02009761
The ClinicalTrials.gov registry entry for NCT02009761 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 655064 is the first listed.
NCT02009761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02009761 about?
NCT02009761 is a clinical study titled "Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).". BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.
What is the current status of trial NCT02009761?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-12-18. Estimated completion is 2016-04-26.
What interventions are being tested in trial NCT02009761?
The interventions under investigation include: BI 655064 (DRUG).
Who is sponsoring clinical trial NCT02009761?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.